Generic Name and Formulations:
Sulfamethoxazole 400mg, trimethoprim 80mg; scored tabs.
Sun Pharmaceutical Industries
Indications for BACTRIM:
Susceptible infections including UTIs (not for initial uncomplicated episodes), shigellosis, prophylaxis and treatment of Pneumocystis jiroveci pneumonia (PJP), travelers' diarrhea or acute exacerbations of chronic bronchitis in adults, acute otitis media in children.
1 DS tab or 2 regular tabs every 12 hours for 5 days (shigellosis, travelers' diarrhea), or 10–14 days (UTIs), or 14 days (bronchitis). PJP treatment: 15–20mg/kg per day trimethoprim (75–100mg/kg per day sulfamethoxazole) in equally divided doses every 6 hours for 14–21 days; PJP prophylaxis: one DS tab daily. Renal impairment (CrCl 15–30mL/min): reduce dose by ½; CrCl <15mL/min: not recommended.
<2months: see Contraindications. ≥2months: 8mg/kg per day trimethoprim (40mg/kg per day of sulfamethoxazole) in 2 divided doses at 12 hour intervals for 5 days (shigellosis) or 10 days (otitis media, UTIs). PJP treatment: as adult; PJP prophylaxis or renal impairment: see full labeling.
History of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides. Megaloblastic anemia due to folate deficiency. Pediatrics <2 months. Marked hepatic damage. Severe renal insufficiency when renal status cannot be monitored.
Not for group A β-hemolytic strep. Avoid prolonged administration. Monitor CBCs, urine, and renal function. Hepatic or renal dysfunction. AIDS (increased risk of toxicities). Folate or G6PD deficiency. Severe allergy or bronchial asthma. Malnutrition. Porphyria or thyroid dysfunction. Disorders of potassium metabolism. Monitor for electrolyte abnormalities, hematologic toxicity. Maintain adequate hydration. Discontinue at 1st sign of skin rash or any other hypersensitivity reactions. Elderly. Pregnancy (Cat.D). Nursing mothers.
Sulfonamide + folic acid inhibitor.
Caution with concomitant CYP2C8, 2C9, or OCT2 substrates. May potentiate oral anticoagulants (eg, warfarin), hypoglycemics, phenytoin, methotrexate, digoxin; monitor. May be potentiated by indomethacin. May increase risk of thrombocytopenia with diuretics (esp. thiazides). Nephrotoxicity with cyclosporine in renal transplant. Megaloblastic anemia with >25mg/week doses of pyrimethamine. May antagonize tricyclic antidepressants. May interfere with assays for serum methotrexate, creatinine. PJP treatment: avoid leucovorin.
Nausea, vomiting, anorexia, allergic skin reactions, blood dyscrasias (eg, megaloblastic anemia), hemolysis, hepatic or renal toxicity, crystalluria, pancreatitis, photosensitivity, drug fever, rash (may be serious, eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), hypoglycemia, hyperkalemia, hyponatremia; C. difficile associated diarrhea.
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments